Propanc Biopharma, Inc. (PPCB)
USD 5.5
(-25.98%)
USD 5.5
(-25.98%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -1.53 Million USD | 13.54% |
| 2023 | -1.77 Million USD | 10.76% |
| 2022 | -1.99 Million USD | -9.86% |
| 2021 | -1.81 Million USD | 48.14% |
| 2020 | -3.49 Million USD | -33.64% |
| 2019 | -2.61 Million USD | 33.97% |
| 2018 | -3.95 Million USD | 31.01% |
| 2017 | -5.74 Million USD | 16.78% |
| 2016 | -6.89 Million USD | -304.41% |
| 2015 | -1.7 Million USD | -124.06% |
| 2014 | -761.22 Thousand USD | 44.11% |
| 2013 | -1.36 Million USD | 88.25% |
| 2012 | -11.58 Million USD | -418.47% |
| 2011 | -2.23 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -438.06 Thousand USD | -5.0% |
| 2024 Q3 | -420.87 Thousand USD | 3.92% |
| 2024 Q4 | -259.89 Thousand USD | 38.25% |
| 2024 Q1 | -417.21 Thousand USD | -99.05% |
| 2023 FY | -1.77 Million USD | 10.76% |
| 2023 Q1 | -572.83 Thousand USD | 4.4% |
| 2023 Q4 | -209.6 Thousand USD | 45.73% |
| 2023 Q3 | -386.2 Thousand USD | 36.48% |
| 2023 Q2 | -608 Thousand USD | -6.14% |
| 2022 Q3 | -502.18 Thousand USD | -24.47% |
| 2022 FY | -1.99 Million USD | -9.86% |
| 2022 Q4 | -599.19 Thousand USD | -19.32% |
| 2022 Q2 | -403.46 Thousand USD | 16.99% |
| 2022 Q1 | -486.03 Thousand USD | 33.14% |
| 2021 FY | -1.81 Million USD | 48.14% |
| 2021 Q1 | -383.16 Thousand USD | 35.5% |
| 2021 Q3 | -427.95 Thousand USD | -56.13% |
| 2021 Q4 | -726.93 Thousand USD | -69.86% |
| 2021 Q2 | -274.09 Thousand USD | 28.47% |
| 2020 Q3 | -607.16 Thousand USD | 56.12% |
| 2020 Q4 | -594.07 Thousand USD | 2.16% |
| 2020 FY | -3.49 Million USD | -33.64% |
| 2020 Q1 | -909.41 Thousand USD | -8.74% |
| 2020 Q2 | -1.38 Million USD | -52.14% |
| 2019 Q2 | -757.82 Thousand USD | -68.83% |
| 2019 Q3 | -571.72 Thousand USD | 24.56% |
| 2019 Q4 | -836.33 Thousand USD | -46.28% |
| 2019 FY | -2.61 Million USD | 33.97% |
| 2019 Q1 | -448.87 Thousand USD | 12.29% |
| 2018 Q3 | -807.13 Thousand USD | 43.83% |
| 2018 Q2 | -1.43 Million USD | -19.36% |
| 2018 Q1 | -1.2 Million USD | -8.51% |
| 2018 Q4 | -511.75 Thousand USD | 36.6% |
| 2018 FY | -3.95 Million USD | 31.01% |
| 2017 FY | -5.74 Million USD | 16.78% |
| 2017 Q4 | -1.1 Million USD | 28.29% |
| 2017 Q3 | -1.54 Million USD | 18.95% |
| 2017 Q2 | -1.9 Million USD | -62.57% |
| 2017 Q1 | -1.17 Million USD | 66.02% |
| 2016 FY | -6.89 Million USD | -304.41% |
| 2016 Q1 | -1 Million USD | -43.62% |
| 2016 Q2 | -1.14 Million USD | -13.54% |
| 2016 Q3 | -1.29 Million USD | -12.85% |
| 2016 Q4 | -3.45 Million USD | -167.72% |
| 2015 Q1 | -238.13 Thousand USD | -93.79% |
| 2015 Q4 | -701.44 Thousand USD | -35.79% |
| 2015 Q3 | -516.56 Thousand USD | -107.09% |
| 2015 Q2 | -249.44 Thousand USD | -4.75% |
| 2015 FY | -1.7 Million USD | -124.06% |
| 2014 Q3 | -104.31 Thousand USD | 53.73% |
| 2014 FY | -761.22 Thousand USD | 44.11% |
| 2014 Q1 | -308.57 Thousand USD | -62.6% |
| 2014 Q2 | -225.45 Thousand USD | 26.94% |
| 2014 Q4 | -122.88 Thousand USD | -17.8% |
| 2013 Q3 | -229.36 Thousand USD | 48.68% |
| 2013 Q4 | -189.77 Thousand USD | 17.26% |
| 2013 FY | -1.36 Million USD | 88.25% |
| 2013 Q1 | -495.98 Thousand USD | 80.51% |
| 2013 Q2 | -446.89 Thousand USD | 9.9% |
| 2012 Q2 | -2.87 Million USD | 6.34% |
| 2012 Q3 | -3.09 Million USD | -7.49% |
| 2012 Q1 | -3.07 Million USD | -368.87% |
| 2012 FY | -11.58 Million USD | -418.47% |
| 2012 Q4 | -2.54 Million USD | 17.78% |
| 2011 Q3 | -508.49 Thousand USD | -3.28% |
| 2011 FY | -2.23 Million USD | 0.0% |
| 2011 Q4 | -655.63 Thousand USD | -28.94% |
| 2011 Q2 | -492.36 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -15.023% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 69.55% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 91.393% |
| Nascent Biotech, Inc. | -2.22 Million USD | 31.115% |
| Rebus Holdings, Inc. | -664 Thousand USD | -131.333% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.877% |
| Qrons Inc. | -643.67 Thousand USD | -138.637% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -294.293% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.233% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -269.706% |
| Skye Bioscience, Inc. | -13.67 Million USD | 88.765% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.86% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 131.253% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -486.892% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.974% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 46.113% |
| Mesoblast Limited | -84.14 Million USD | 98.175% |
| Marizyme, Inc. | -34.08 Million USD | 95.494% |
| Genus plc | 6.4 Million USD | 124.001% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 115.767% |
| Pharming Group N.V. | -4.87 Million USD | 68.521% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 22.675% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -64.922% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 81.604% |
| ContraFect Corporation | -56.88 Million USD | 97.3% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 66.276% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -9.562% |
| IMV Inc. | -38.67 Million USD | 96.028% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 44.161% |
| MultiCell Technologies, Inc. | -722.81 USD | -212410.757% |
| ONE Bio Corp. | 13.68 Million USD | 111.227% |
| Accustem Sciences Inc. | -3.74 Million USD | 59.0% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.396% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -217.982% |
| Q BioMed Inc. | -3.44 Million USD | 55.42% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 143.391% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 41.54% |
| Biomind Labs Inc. | -1 Million USD | -52.144% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.206% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 47.056% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 76.895% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 17.61% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -5028.369% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.321% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 20.519% |
| GB Sciences, Inc. | -1.42 Million USD | -8.134% |
| Alpha Cognition Inc. | -9.7 Million USD | 84.174% |
| HST Global, Inc. | -140.9 Thousand USD | -990.115% |
| CSL Limited | 3.7 Billion USD | 100.041% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -36.549% |
| Halberd Corporation | -75.05 Thousand USD | -1946.701% |
| Enzolytics Inc. | -2.14 Million USD | 28.516% |
| Agentix Corp. | -1.37 Million USD | -11.977% |
| Resverlogix Corp. | -12.74 Million USD | 87.952% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 51.518% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.639% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -47.131% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 47.386% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 2.742% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 54.888% |
| AVAX Technologies, Inc. | 6.69 Million USD | 122.95% |
| Zenith Capital Corp. | -8.94 Million USD | 82.824% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.631% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8717.226% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 37.44% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -795.606% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 23.38% |
| Kadimastem Ltd | -3.04 Million USD | 49.476% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -56.094% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -22.297% |
| BioStem Technologies, Inc. | -7.77 Million USD | 80.254% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -746.378% |
| LadRx Corporation | -3.82 Million USD | 59.827% |
| Cell Source, Inc. | -4.32 Million USD | 64.487% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -123.604% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -123.604% |
| NovAccess Global Inc. | -2.46 Million USD | 37.73% |
| Affymax, Inc. | -15.04 Million USD | 89.791% |
| Itoco Inc. | -919.14 Thousand USD | -67.118% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 63.759% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -37.27% |
| Mobile Lads Corp. | -554.55 Thousand USD | -176.99% |
| CytoDyn Inc. | -18.05 Million USD | 91.494% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -6002.698% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -597.957% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -172.0% |
| SYBLEU INC | -149.18 Thousand USD | -929.661% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 15.431% |
| International Stem Cell Corporation | -663 Thousand USD | -131.682% |
| Bioxytran, Inc. | -3.82 Million USD | 59.791% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2818.026% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -7451.863% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 95.764% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 5.065% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -108.749% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 50.625% |
| Neutra Corp. | -229.48 Thousand USD | -569.343% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 91.242% |
| PureTech Health plc | -146.19 Million USD | 98.949% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 92.853% |
| IXICO plc | -1.43 Million USD | -6.893% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 83.816% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.739% |
| CSL Limited | 3.81 Billion USD | 100.04% |
| Cellectis S.A. | -108.85 Million USD | 98.589% |